Literature DB >> 18157012

Inhibitory effect of RNA pool complexity on stimulatory capacity of RNA-pulsed dendritic cells.

Miran Javorovic1, Susanne Wilde, Anke Zobywalski, Elfriede Noessner, Volker Lennerz, Thomas Wölfel, Dolores J Schendel.   

Abstract

Tumor cells that show downregulation of their tumor-associated antigens (TAAs) may be able to escape immune-mediated elimination. Therefore, efficient vaccine strategies attempt to target multiple TAAs simultaneously. This is easily achieved in dendritic cell (DC)-based vaccines by introducing antigens in the form of RNA. Although insufficient message may hinder adequate expression of individual TAAs when using total-tumor RNA, high amounts of individual RNAs as pools yield DCs presenting high numbers of specific peptide-major histocompatibility complex ligands with epitopes derived from different TAAs. We used the transfer of RNAs encoding the well-defined melanoma TAAs tyrosinase, Melan-A, CDK4mut, gp100, SNRP116mut, and GPNMBmut to characterize DCs at the levels of transfected RNA, expressed protein and peptide-major histocompatibility complex ligand presentation. TAA-encoding RNA was rapidly degraded in the DCs, allowing only a single surge in protein expression shortly after transfection. We compared the functional capacity of DCs transfected with pools of 3 versus 6 RNAs. Whereas functional assays demonstrated a decrease in stimulatory capacity of DCs transfected with a pool of 3 RNAs by only 30% as compared with single RNAs, a 60% loss was seen with 6 RNAs. We conclude that larger RNA pools result in diminished presentation of individual epitopes and suggest that smaller pools of RNA be transfected into separate DC populations which are then pooled to create multiplex vaccines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18157012     DOI: 10.1097/CJI.0b013e31815a1202

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  7 in total

1.  mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma.

Authors:  Troels Holz Borch; Lotte Engell-Noerregaard; Trine Zeeberg Iversen; Eva Ellebaek; Özcan Met; Morten Hansen; Mads Hald Andersen; Per Thor Straten; Inge Marie Svane
Journal:  Oncoimmunology       Date:  2016-07-08       Impact factor: 8.110

Review 2.  Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma.

Authors:  Christiane Geiger; Elfriede Nössner; Bernhard Frankenberger; Christine S Falk; Heike Pohla; Dolores J Schendel
Journal:  J Mol Med (Berl)       Date:  2009-03-07       Impact factor: 4.599

3.  Generation of allo-restricted peptide-specific T cells using RNA-pulsed dendritic cells: A three phase experimental procedure.

Authors:  Susanne Wilde; Christiane Geiger; Slavoljub Milosevic; Barbara Mosetter; Sabine Eichenlaub; Dolores J Schendel
Journal:  Oncoimmunology       Date:  2012-03-01       Impact factor: 8.110

4.  T-Cells Expressing a Highly Potent PRAME-Specific T-Cell Receptor in Combination with a Chimeric PD1-41BB Co-Stimulatory Receptor Show a Favorable Preclinical Safety Profile and Strong Anti-Tumor Reactivity.

Authors:  Nadja Sailer; Ina Fetzer; Melanie Salvermoser; Monika Braun; Doris Brechtefeld; Christian Krendl; Christiane Geiger; Kathrin Mutze; Elfriede Noessner; Dolores J Schendel; Maja Bürdek; Susanne Wilde; Daniel Sommermeyer
Journal:  Cancers (Basel)       Date:  2022-04-14       Impact factor: 6.575

5.  Codon optimization of the human papillomavirus E7 oncogene induces a CD8+ T cell response to a cryptic epitope not harbored by wild-type E7.

Authors:  Felix K M Lorenz; Susanne Wilde; Katrin Voigt; Elisa Kieback; Barbara Mosetter; Dolores J Schendel; Wolfgang Uckert
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

Review 6.  Lentivirus-Induced Dendritic Cells (iDC) for Immune-Regenerative Therapies in Cancer and Stem Cell Transplantation.

Authors:  Renata Stripecke
Journal:  Biomedicines       Date:  2014-08-21

7.  Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy.

Authors:  Kathrin Davari; Tristan Holland; Laura Prassmayer; Giulia Longinotti; Kenneth P Ganley; Lisa J Pechilis; Iulia Diaconu; Prashant R Nambiar; Michael S Magee; Dolores J Schendel; Daniel Sommermeyer; Christian Ellinger
Journal:  J Immunother Cancer       Date:  2021-03       Impact factor: 13.751

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.